Division of Hematology and Oncology

From left, Benjamin Brown, Christine Lovly, MD, PhD, Yun-Kai Zhang, PhD, Jens Meiler, PhD, and colleagues are exploring new ways to understand resistance to targeted cancer therapy drugs.

Study reframes approach to targeted therapy resistance

When a tumor mutates and develops resistance to a targeted therapy, researchers often focus on the acquisition of new mutations within the drug target as they seek an alternative treatment, but a team of Vanderbilt scientists has shown this may not be sufficient.

Longtime colleagues and friends Curt Thorne, left, and Terry Burke enjoyed sailing together.

Bladder cancer research fund honors mentor’s lasting influence

The Terry Burke Fund for Bladder Cancer Research at Vanderbilt-Ingram Cancer Center is supporting a range of discovery research aimed at improving outcomes for bladder cancer patients, and it is helping train the next generation of bladder cancer physician-scientists.

Investigators map genomic landscape of very rare cancer

A team of Vanderbilt researchers mapped out the genomic landscape of a metastatic malignant proliferating tricholemmal tumor and identified a targeted treatment for this very rare cancer.

Grant supports novel imaging initiative to enhance cancer care

A Vanderbilt initiative to develop predictive imaging technologies that clinicians can use to better match patients with personalized care has received National Cancer Institute (NCI) funding.

Spalluto, Lewis to lead VA lung screening initiative

Lucy Spalluto, MD, assistant professor of Radiology and Radiological Sciences, and Jennifer Lewis, MD, MS, instructor in Medicine, have been selected to co-lead the Veterans Affairs — Partnership to increase Access to Lung Screening (VA-PALS) National Program Evaluation.

Dae Kwang Jung, left, Brian Engelhardt, MD, MSCI, and colleagues are studying why stem cell transplant patients are at risk of developing diabetes.

Research explores link between stem cell transplant, diabetes

About a decade ago, at the beginning of his career in academic medicine, Brian Engelhardt, MD, MSCI, noticed that many of his patients receiving a stem cell transplant for their blood cancer ended up with diabetes.

1 8 9 10 11 12 15